4.6 Review

Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice

期刊

BONE
卷 78, 期 -, 页码 216-224

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2015.05.016

关键词

Osteoporosis; Epidemiology; Trabecular bone score (TBS); Fragility fracture; Bone mineral density; FRAX

资金

  1. Alliance for Better Bone Health
  2. AMGEN
  3. MSD
  4. Eli Lilly
  5. Servier
  6. Shire
  7. Consilient Healthcare
  8. Internis Pharma
  9. Firefly Pharma
  10. Medimaps
  11. GSK
  12. Danone
  13. Takeda
  14. Lilly
  15. Merck
  16. Opko Ireland
  17. GE Healthcare Lunar
  18. Bayer
  19. General Electric
  20. Hologic
  21. Merck Research Labs
  22. Novartis
  23. Novo Nordisk
  24. Nycomed
  25. Ono
  26. Pfizer
  27. ProStrakan
  28. Roche
  29. Sanofi-Aventis
  30. Tethys
  31. UBS
  32. Warner-Chilcott
  33. Alexion
  34. Abiogen
  35. Bruno Farmaceutici
  36. NPS
  37. SPA
  38. Medtronic
  39. Astalis
  40. Astra Zeneca
  41. Ache
  42. EMS
  43. Grupogen-AC Farmaceutica
  44. Hypermarcas
  45. Sanofi
  46. Uniao Quimica
  47. Zodiac
  48. Negma
  49. Wyeth
  50. GlaxoSmithKline
  51. Merckle
  52. Theramex
  53. UCB
  54. Merck Sharp and Dohme
  55. Rottapharm
  56. IBSA
  57. Genevrier
  58. Teijin
  59. Teva
  60. Ebewee Pharma
  61. Analis
  62. Nolver
  63. Bristol Myers Squibb
  64. D3A
  65. Medical Research Council [U1475000001, MC_U147585819, MR/K006312/1, MC_U147585824, G0400491, MC_UU_12011/1, MC_UP_A620_1014, MC_U147585827] Funding Source: researchfish
  66. National Institute for Health Research [NF-SI-0513-10085, NF-SI-0508-10082] Funding Source: researchfish
  67. MRC [MR/K006312/1, MC_U147585819, MC_U147585827, G0400491] Funding Source: UKRI

向作者/读者索取更多资源

Trabecular bone score (TBS) is a recently-developed analytical tool that performs novel grey-level texture measurements on lumbar spine dual X-ray absorptiometry (DXA) images, and thereby captures information relating to trabecular microarchitecture. In order for TBS to usefully add to bone mineral density (BMD) and clinical risk factors in osteoporosis risk stratification, it must be independently associated with fracture risk, readily obtainable, and ideally, present a risk which is amenable to osteoporosis treatment. This paper summarizes a review of the scientific literature performed by a Working Group of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Low TBS is consistently associated with an increase in both prevalent and incident fractures that is partly independent of both clinical risk factors and areal BMD (aBMD) at the lumbar spine and proximal femur. More recently, TBS has been shown to have predictive value for fracture independent of fracture probabilities using the FRAX (R) algorithm. Although TBS changes with osteoporosis treatment, the magnitude is less than that of aBMD of the spine, and it is not clear how change in TBS relates to fracture risk reduction. TBS may also have a role in the assessment of fracture risk in some causes of secondary osteoporosis (e.g., diabetes, hyperparathyroidism and glucocorticoid-induced osteoporosis). In conclusion, there is a role for TBS in fracture risk assessment in combination with both aBMD and FRAX. (C) 2015 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据